Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other financing activities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other financing activities for 8 consecutive years, with -$315000.0 as the latest value for Q3 2025.

  • Quarterly Other financing activities fell 730.0% to -$315000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 34.94% year-over-year, with the annual reading at $1.5 million for FY2025, 177.43% up from the prior year.
  • Other financing activities for Q3 2025 was -$315000.0 at Gyre Therapeutics, down from $1.7 million in the prior quarter.
  • The five-year high for Other financing activities was $1.7 million in Q2 2025, with the low at -$315000.0 in Q3 2025.